S1R.F Shanghai Pharmaceuticals Holding Co. Ltd
- Market cap
- EUR 4.52B
- P/E
- 7.2x
- P/B
- 0.43x
- ROE
- 7.7%
- Dividend yield
- 4.63%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is S1R.F undervalued?
Graham numberS1R.F trades 62.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Pharmaceuticals Holding Co. Ltd fundamental analysis
No fundamental analysis for Shanghai Pharmaceuticals Holding Co. Ltd yet.
Shanghai Pharmaceuticals Holding Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Pharmaceuticals Holding Co. Ltd
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric and neurological, tumor, cardiovascular, digestive metabolism, psychoneurotic, n…
Full company profileShanghai Pharmaceuticals Holding Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Pharmaceuticals Holding Co. Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 121B | 131B | 159B | 187B | 192B | 216B | 232B | 260B | 275B | 284B | 297B |
| Gross Profit | 14.2B | 16.7B | 22.6B | 26.8B | 27.4B | 28.5B | 30.5B | 31.3B | 30.6B | 30.4B | 31.3B |
| Operating Income | 3.79B | 4.26B | 5.23B | 6.76B | 8.14B | 7.93B | 8.78B | 9.57B | 9.69B | 9.28B | 10.7B |
| EBITDA | - | 6.92B | 7.71B | 9.55B | 10.7B | 10.7B | 12.7B | 11.1B | 12.3B | 14.4B | 11.5B |
| Net Income | 3.20B | 3.52B | 3.88B | 4.08B | 4.50B | 5.09B | 5.62B | 3.77B | 4.55B | 5.72B | 6.11B |
| EPS | - | 1.31 | 1.37 | 1.44 | 1.58 | 1.79 | 1.52 | 1.02 | 1.23 | 1.54 | 1.65 |
| Balance Sheet | |||||||||||
| Total Assets | 82.7B | 94.3B | 127B | 137B | 149B | 163B | 198B | 212B | 221B | 233B | 242B |
| Total Liabilities | 45.9B | 54.7B | 80.4B | 87.6B | 94.4B | 104B | 120B | 132B | 137B | 143B | 148B |
| Shareholders' Equity | 31.6B | 34.0B | 39.0B | 41.7B | 45.4B | 49.4B | 67.1B | 68.5B | 71.7B | 75.9B | 79.3B |
| Cash & Short-term Investments | 12.0B | 14.8B | 18.7B | 18.2B | 22.3B | 22.4B | 27.4B | 30.5B | 35.7B | 32.7B | 32.4B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.95B | 2.65B | 3.14B | 6.02B | 6.84B | 5.06B | 4.74B | 5.23B | 5.83B | 6.15B | - |
| Capital Expenditure | 2.12B | 2.01B | 1.94B | 2.75B | 3.01B | 4.12B | 2.68B | 2.97B | 2.40B | 2.33B | 2.07B |
| Free Cash Flow | - | 642M | 1.19B | 3.27B | 3.83B | 943M | 2.06B | 2.26B | 3.43B | 3.83B | 5.06B |
| Ratios | |||||||||||
| ROE | 10.1% | 10.3% | 9.9% | 9.8% | 9.9% | 10.3% | 8.4% | 5.5% | 6.4% | 7.5% | 7.7% |
| ROA | 3.9% | 3.7% | 3.1% | 3.0% | 3.0% | 3.1% | 2.8% | 1.8% | 2.1% | 2.5% | 2.5% |
| Net Profit Margin | 2.6% | 2.7% | 2.4% | 2.2% | 2.3% | 2.4% | 2.4% | 1.4% | 1.7% | 2.0% | 2.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shanghai Pharmaceuticals Holding Co. Ltd dividends
- Dividend yield
- 4.63%
- Forward dividend
- 0.06 EUR
- Payout ratio
- 48.9%
- Ex-dividend date
- Sep 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 2.80B | 0.76 | 48.9% |
| 2024 | CNY 3.60B | 0.97 | 79.2% |
| 2023 | CNY 3.98B | 1.08 | 105.7% |
| 2022 | CNY 3.09B | 0.84 | 55.1% |
| 2021 | CNY 2.68B | 0.94 | 52.5% |
| 2020 | CNY 2.42B | 0.85 | 53.8% |
| 2019 | EUR 2.58B | 0.91 | 63.3% |
| 2018 | EUR 2.36B | 0.83 | 60.8% |
| 2017 | EUR 1.75B | 0.65 | 49.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shanghai Pharmaceuticals Holding Co. Ltd
- Insiders 40.06%
- Institutions 12.81%
- Public & others 47.13%
- Shares outstanding 919M
- Free float 1.55B
Shanghai Pharmaceuticals Holding Co. Ltd company profile
- Company name
- Shanghai Pharmaceuticals Holding Co. Ltd
- Ticker
- S1R.F
- ISIN
- CNE1000012B3
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 49,608
- Fiscal year end
- December
- Address
- Shanghai Pharmaceutical Building, Shanghai, China, 200020
- Phone
- 86 21 6373 0908
- Website
- sphchina.com
About Shanghai Pharmaceuticals Holding Co. Ltd
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric and neurological, tumor, cardiovascular, digestive metabolism, psychoneurotic, neoplasm, respiratory system, and anti-infection diseases, as well as invests in equity. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores. Shanghai Pharmaceuticals Holding Co., Ltd. was incorporated in 1994 and is headquartered in Shanghai, China.
Shanghai Pharmaceuticals Holding Co. Ltd management
9- Mr. Qiuhua YangExecutive Chairman · born 1972
- Mr. Bo Shen CPAPresident & Executive Director · born 1973
- Ms. Yadong ZhouVP & CFO · born 1972
- Mr. Yongzhong LiExecutive President & Executive Director · born 1970
- Mr. Ming DongExecutive Director · born 1976
- Mr. Tao ZhongVP, Board Secretary & Joint Company Secretary · born 1972
- Ms. Shuai ShaoVice President · born 1988
- Ms. Pui Kiu WongJoint Company Secretary
- Linqiong DongSecurities Affairs Representative